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Abstract.  We have proposed a  model in which fibro- 
blast growth factor (FGF) signalling  requires the inter- 
action of FGF with at least two FGF receptors, a hep- 
aran  sulfate proteoglycan (HSPG) and a tyrosine 
kinase.  Since FGF may be a key mediator of skeletal 
muscle differentiation,  we examined the synthesis of 
glycosaminoglycans in MM14 skeletal muscle myo- 
blasts and their participation in FGF signalling.  Prolif- 
erating and differentiated MM14 cells exhibit similar 
levels of HSPG, while differentiated cells exhibit re- 
duced levels of chondroitin  sulfate proteoglycans and 
heparan  sulfate chains.  HSPGs, including  syndecan, 
present in proliferating  cells bind bFGF, while the ma- 
jority of chondroitin  sulfate and heparan sulfate chains 
do not.  Treatment of skeletal muscle cells with chlo- 
rate,  a reversible inhibitor of glycosaminoglycan sulfa- 
tion,  was used to examine the requirement of sulfated 
proteoglycans for FGF signalling.  Chlorate treatment 
reduced glycosaminoglycan sulfation by 90%  and bind- 
ing of FGF to high affinity sites by 80%.  Chlorate 
treatment of MM14 myoblasts abrogated the biological 
activity of acidic, basic, and Kaposi's sarcoma FGFs 
resulting in terminal differentiation.  Chlorate inhibi- 
tion of FGF signalling was reversed by the simultane- 
ous addition of sodium sulfate or heparin.  Further sup- 
port for a direct role of heparan  sulfate proteoglycans 
in fibroblast growth factor signal transduction was 
demonstrated by the ability of heparitinase  to inhibit 
basic FGF binding and biological activity.  These re- 
suits suggest that activation of FGF receptors by acidic, 
basic or Kaposi's sarcoma FGF requires simultaneous 
binding to a  HSPG and the tyrosine kinase receptor. 
Skeletal muscle differentiation in vivo may be depen- 
dent on FGFs, FGF tyrosine kinase receptors,  and 
HSPGs. The regulation of these molecules may then 
be expected to have important  implications  for skeletal 
muscle development and regeneration. 
F 
IagOaLAST growth factors (FGF), ~ a family of seven 
related members,  exhibit  pleiotropic biological ac- 
tivities and affinity for heparin (Burgess and Maciag, 
1989; Olwin,  1989; Klagsbrun and Dgmaore,  1991). Their 
affinity for heparin  suggests that heparan sulfate proteogly- 
cans (HSPG) interact with FGF in vivo. Several studies have 
demonstrated that FGF binds to cell surface-derived and ex- 
tracellular  matrix-derived  heparan  sulfate  proteoglycans 
(Gospodarowicz and  Cheng,  1986;  Saksela  et al.,  1988; 
Flanmenhaft  et al., 1989; Flaumenhaft et al., 1990; Saksela 
and Rifldn, 1990; Vlodavsky et al., 1991a,b).  HSPGs have 
been proposed to serve as storage reservoirs for FGF and to 
protect FGF from proteolytic degradation (Gospodarowicz 
and Chang,  1986; Flaumenhaft et al., 1989; Flaumenhaft  et 
al., 1990; Vlodavsky et al., 1991; Vlodavsky et al., 1991a,b). 
We and others have recently proposed that HSPGs are essen- 
tial for basic FGF (bFGF) activity and high affinity binding 
(Bernard  et al.,  1991; Rapraeger et al.,  1991; Yayon et al., 
1991). 
1. Abbreviations  used in this paper: aFGF, acidic FGF; bFGF, basic FGF; 
CSPG,  chondroitin sulfate  proteoglycan;  FGF,  fibroblast  growth factor; 
GAG, glycosaminoglycan;  HSPG,  heparan sulfate proteoglycan;  K-FGF, 
Kaposi's sarcoma FGF; KGF, keratinocyte growth factor. 
A  number of cell surface HSPGs have been described. 
One HSPG that may be involved in FGF action is syndecan, 
a mixed heparan and chondroitin  sulfate proteoglycan.  Syn- 
decan is an integral  membrane protein present on the cell 
surface (Rapraeger  et al.,  1985; Saunders  et al.,  1989).  A 
soluble form is thought  to arise by cleavage of syndecan at 
an  extracellular  site  near  the membrane-spanning  region 
(Rapraeger  and  Bernfield,  1985).  Expression  cloning  of 
FGF-binding  proteins identified  syndecan as a low affinity 
bFGF binding  site (Kiefer  et al.,  1990).  Of additional  in- 
terest is the observation that the glycosaminoglyean  content 
of syndecan can be regulated by growth factors in epithelial 
cells (Rapraeger,  1989).  Thus,  the availability of syndecan 
for FGF binding  could be regulated in a number of ways. 
Among the biological activities described for FGFs is the 
capacity to repress the terminal  differentiation  of skeletal 
muscle cells (Gospodarowicz et al.,  1975; Linkhart et al., 
1981; Lathrop et al., 1985; Clegg et al., 1987). Our previous 
work has been directed at understanding  the mechanisms in- 
volved  in  FGF-mediated  repression  of  skeletal  muscle 
differentiation  using  a mouse skeletal  muscle satellite  cell 
line  (MM14)  as a  model.  Rather  than  directly regulating 
proliferation,  FGF acts to maintain cell growth by repressing 
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1987).  Since this activity cannot be replaced by any other 
known growth factors, these cells provide a unique system 
for studying the mechanisms  involved  in FGF signalling. 
Deprivation of FGF, even in the continued presence of se- 
rum, induces a terminal  differentiation  program,  in which 
the  first observable phenotypic change  is  an  irreversible 
withdrawal from the cell cycle. This permanent loss of FGF 
response is accompanied by a loss of FGF binding capacity 
(Olwin and Hauschka,  1986, 1988). 
Recently, we have shown that heparan sulfate is required 
for the action of bFGF on Swiss 3T3 cells.  This suggested 
a model in which bFGF-mediated signalling in these ceils is 
dependent on simultaneous binding of bFGF to cell surface 
HSPG and a tyrosine kinase.  In this study, we demonstrate 
that chlorate treatment causes a reduction in sulfation of pro- 
teoglycans that correlates with the loss of FGF binding  and 
FGF action.  Furthermore,  we find that all FGFs active in 
MM14 cells including acidic FGF (aFGF), bFGF, and Kapo- 
sis Sarcoma FGF (K-FGF) (Delli-Bovi et al., 1987) require 
heparan sulfate, suggesting a universal requirement of hepa- 
ran sulfate for FGF binding  and signalling. 
Materials and Methods 
Human bFGF was purified from yeltst expressing an artificially constructed 
human bFGF gene as previously described. Bovine acidic FGF was purified 
from bovine brain as previously described (Olwin and Hauschka,  1986). 
K-FGF was kindly provided by Claudio Basllico  (Columbia University, 
New York). Chloramine T for iodinations was purchased from Eastman Ko- 
dak Co. (Rochester,  NY) and Enzymobeads were from BioRad Laborato- 
ries (Richmond, CA).  Na125I was  purchased from DuFont Instruments 
(Wilmington,  DE). Sodium chlorate, sodium sulfate,  and sodium chloride 
were  from  Sigma Chemical Co.  (St.  Louis,  MO).  Heparitinase (E.C. 
4.2.2.8) and Chondroitin ABC lyase were purchased from ICN Biochem- 
icals (Irvine, CA). 
lodination of  aFGF and bFGF 
Iodination of aFGF and bFGF was performed using Chloramine T as previ- 
ously described (Olwin and Hauschka,  1990). The specific activity of both 
FGF,  s was determined using MMI4 thyrnidine incorporation assays and 
averaged 3,000 cpm/fmol on the date of iodination. Radiolabeled  FGF was 
stored at 4~  and was used within two weeks of labeling. 
MMI4 Cell Cycle Exit Assay 
MM14 cells were assayed for exit from the cell cycle as previously described 
(Olwin and Hauschka,  1986).  Briefly,  1,000 cells/well  in a 24-well dish 
were plated and incubated for  14 h, then 2 ~Ci of [3H]thymidine  were 
added and the cells were incubated for an additional 8-10 h. [3H]thymidine 
incorporation was determined using a TriCarb scintillation counter (Pack- 
ard Instruments Co., Downers Grove,  IL). For treatments, the cells were 
plated in the presence of the indicated concentrations of sodium chlorate, 
sodium sulfate,  or heparin in the presence of FGE 
FGF Binding Assay 
Binding of radiolabeled FGF was performed by passnging cells with trypsin 
and plating at 5  x  105 to 1 x  106 cells/35-mm dish in the presence or ab- 
sence of sodium chlorate and/or sodium sulfate. This passage is necessary 
as MM14 cells will contain >10% differentiated cells if grown to densities 
>1  ￿  105 cells/35-mm dish. The cells were allowed to recover for 4 h in 
FIOC containing 15% horse serum with the indicated treatments. The cul- 
tures were washed three times with binding buffer (F10C containing 0.2 
mg/ml BSA, and 25 rnM Hepes,  pH 7.4), and incubated for 3 h at 4~  in 
binding buffer containing 200 pM radiolabeled FGF in the presence and ab- 
sence of I pM unlabeled bFGE Cells were then rapidly washed three times 
with wash buffer (20 mM Hepes, pH 7.4,  150 mM NaC1, 0.2% BSA). The 
remaining washes were  retained and counted on a  LKB  Clinnigamma 
counter: two washes with 1.0 ml of wash buffer containing either 2 M NaC1 
(for bFGF) or 0.75 M NaCI (for aFGF) and two 1.0-mi washes of 20 mM 
sodium acetate, pH 4.0, 2 M NaCI, 0.2% BSA. The washes collected at neu- 
tral pH buffer were designated "low affinity" and the low pH washes were 
designated ~high afl~nity7  Where indicated, nonspecific binding  determined 
in the presence of 1/~M bFGF was subtracted from the total. These levels 
of bFGF were necessary for competition of labeled FGF from both low and 
high affinity binding sites (Rapraeger,  A,, unpublished observations). 
Heparitinase Treatment of  MM14 Cultures 
MM14 cells were grown and assayed for FGF activity in the cell cycle exit 
assay as described above  except  that 0.0012  IU/mi of heparitinase (EC 
4.2.2.8) were added when the cells were plated and again at 2 h after plating. 
The cells were then incubated for the duration of the assay in the presence 
of a total of 0.0024 IU/ml of heparitinase. For binding analyses,  the cells 
were passaged  and plated at described above except cells were incubated 
at 37~  for 4 h in the presence of 0.0012 IU/ml heparitinase.  Binding of 
125I-bFGF was then performed as described above. 
Isolation and Analysis of  MM14 
Cell Glycosaminoglycans 
MMI4 cultures  were  labeled  for  24  h in I00  ~tCilml  [35S]O42-  (ICN  Radio- 
chemicals)  in  the  presence  or  absence  of  10  mM  sodium  chlorate.  The  cul- 
tures  were  extracted  in I0  mM  Tris/HCl  (pH  Z5), 8 M urea,  and  0.1% Tri- 
ton X-100, then  chromatographed on DEAE--Sephacel (Pharmacia Fine 
Chemicals, Piscataway, N J) as described previously  (Rasmussen and 
Rapracger,  1988).  Fractions  eluted  in 10 mM  Tris/HCl (pH 7.5)  in  a salt 
gradient  from  0.15-0.8  M were  brought  to  0.15  M  salt,  treated  with  or  with- 
out  0.05  U/mi  chondroitinase  ABC for  120  min  at  37~  to  cleave  chondroi- 
tin sulfate glycosaminoglycan,  and spotted on cationic nylon (Zeta-Probe; 
Bio-Rad  Laboratories). The spotted fractions were then treated with or 
without nitrous acid for determination  of mdiotabel in h~ran sulfate (Ras- 
mussen and Rapraeger,  1988; Rapraeger and Yeaman, 1989). Additionally, 
the binding of glycusaminoglycan  chains or fragments was quantified  by 
their release from the cationic nylon blot by a wash in 0.7 M NaCI in 10 
mM Tris/HC1 (pH 8.0) (Rasmussen and Rapraeger,  1988;  Rapraeger  and 
Yeaman, 1989). This identified free chains that: (a) chromatograph with a 
Kay of 0.7 on Sepharose  CL-6B in 8 M urea, similar to chains identified 
in a number of other cells (Bie~ki  and Conrad, 1984; Kjell6n et al., 
1985; Rapraeger and Yeaman,  1989); (b) are unchanged in size by ~dkaline 
E-elimination to release core protein; and (c) are susceptible to degradation 
with nitrous acid or heparitinase (data not shown). These are identified as 
GAG fragments in Fig.  1. 
Binding of the glycosaminoglycan  fractions to bFGF was determined 
using a 1.0 mi affinity column of  human recombinant  bFGF bound to CNBr- 
Sepharose.  Proteoglycan/GAG  samples purified  on DEAE-Sephacel were 
pooled, loaded on the FGF-aflinity  column in I0 mM Tris/HCl (pH 7.5) 
containing 0.15 M  NaCl, and then eluted in a salt gradient ranging from 
0.15 to 2.0 M NaC1. Fractions were diluted to 0.15 M NaC1 and spotted 
on cationic nylon for identification as described above. 
Results 
We have  previously demonstrated that bFGF signalling in 
Swiss 3T3 cells in dependent on heparan sulfate as shown by 
reduction  of bFGF  activity  on chlorate-  or  heparithmse- 
treated  cells.  We  attributed  the  effectiveness  of chlorate 
treatment  to reduction of proteoglycan sulfation. Here, we 
examine the effect of chlorate treatment on reduction of pro- 
teoglycan sulfation. Here, we examine the effect of chlorate 
treatment on proteoglycan sulfation, FGF binding, and FGF 
activity on MM14 cells. 
FGF Binding to Heparan Sulfate in MMI4 Cultures 
Proteoglycan Synthesis in Proliferating and Di~erentiated 
MM14 Cultures.  Newly  synthesized  glycosaminoglycans 
(GAG) of proliferating  and differentiated  MM14 cells were 
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Figure 2. HSPG in proliferating MM14 ceils binds to bFGE MM14 
myoblasts were labeled with [3sS]04 and harvested as described 
for Fig. 1. The extract was then chromatographed on bFGF affinity 
column developed with a NaCI gradient from 0-2.0 M NaCI. Frac- 
tions were analyzed for GAG fragments  ( ..... ), HSPG (o) and 
chondroitin sulfate (o) as described for Fig. 1. Syndecan was de- 
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Figure 1. Proteoglycan synthesis in proliferating and differentiated 
MM14 cells. Proliferating MM14 myoblasts (A) and differentiated 
MM14 cells  (B) were labeled  with  100 #Ci/ml  [3sS]O42-, har- 
vested, and chromatographed on DEAE-Sephacel as described in 
Materials and Methods. Fractions were then diluted to 0.15 M NaC1 
and spotted onto cationic nylon either before or after a 120-rain 
treatment with 0.05 U/ml chondroitin ABCase at 37~  to identify 
chondroitin sulfate. Alternatively, untreated samples bound to cat- 
ionic nylon were subjected to treatment with 0.65 M NaCI to re- 
move GAG fragments and/or HNO2 to identify heparan  sulfate. 
( .... , GAG fragments; e, cpm in chondroitin sulfate; o, cpm in 
heparan sulfate proteoglycan). 
examined  by  DEAE-Sephacel  chromatography  (Fig.  1). 
Three distinct populations of sulfate-labeled material were 
seen: (a) chondroitin sulfate proteoglycan, which was sus- 
ceptible  to  treatment  with  chondroitin  ABC  lyase;  (b) 
HSPG, identified by its retention on cationic nylon and its 
susceptibility to nitrous acid; and (c) HSPGs, identified by 
their susceptibility to nitrous acid and elution from Sepha- 
rose CL=6B with a K,, of 0.7, suggesting a size of 8-10 kD. 
The size of the putative fragments is unaffected by alkali 
treatment  suggesting  that  they  are  not  linked  to  a  core 
protein. 
The expression of  proteoglycans changes upon differentia- 
tion of MM14 cells. Significant reductions in both chondroi- 
tected in the fractions by spotting aliquots onto cationic nylon fol- 
lowed by staining with mAb281.2. Syndecan elution peaked at frac- 
tion 18 corresponding to the peak of HSPG elution. 
tin sulfate proteoglycan (CSPG) and heparan sulfate glycos- 
aminoglycan fragments are seen. However, the total amount 
of  HSPG appears relatively unchanged. Nonetheless, exami- 
nation of syndecan, a specific HSPG, demonstrates that it is 
expressed on proliferating but not differentiated MM14 cells 
(Kudia,  A.,  A.  Lop~s,  A.  Rapraeger,  and  B.  B.  Olwin, 
manuscript in preparation). 
HSPG on Proliferating MMI4 Cells Binds FGE Sulfate- 
labeled glycosaminoglycans from proliferating MM14 cells 
were applied to a bFGF affinity column and binding of the 
three distinct populations was examined (Fig. 2).  Greater 
than 90% of the applied material bound to the column in the 
presence of 0.15 M  NaC1 was eluted from the column at a 
salt concentration of <0.5 M NaCI. The material requiring 
higher  concentrations  of NaC1  for  elution  included  the 
majority of the HSPG, '~30% of the CSPG and 20% of the 
heparan sulfate fragments (Fig. 2). Syndecan, identified by 
immunochemical methods, is retained on the bFGF affinity 
column and co-elutes with the HSPG, demonstrating that it 
is a FGF-binding HSPG present in MM14 cells. 
Chlorate Reduces Suifation of N~ly Synthesized Gly- 
cosamtnoglycans  in MM14 Myoblasts.  Chlorate ion is  a 
competitive inhibitor of the ATP-sulfurylase responsible for 
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Figure  3. Treatment  with chlo- 
rate reduces the sulfation of 
newly synthesized glycosami- 
noglycans. MM14 myoblasts 
were labeled for 5 h in medi- 
um  containing  100  #Ci/ml 
[35S]O42- and 5 #Ci/rni [3H]- 
glucosamine  with (0) or with- 
out (o) 10 mM sodium chlo- 
rate.  The  monolayers vcvre 
extracted in 10 mM Tris/HC1 
(pH  7.5) containing 0.15 M 
NaCI, 8 M urea, and 0.1% Tri- 
ton  X-100, and  then  loaded 
onto  DEAE-Sephacel  and 
eluted with a gradient of  NaC1 
ranging from 0.1--0.8 M. Ali- 
quots  of  fractions  were ei- 
ther treated with chondroitin 
ABCase and spored on cat- 
ionic nylon to quantify chon- 
droitin sulfate or spored di- 
rectly and subjected to nitrous 
acid degradation to quantify 
heparan  snifate. (HA, hyal- 
uronic acid; HS, heparan sul- 
fate; CS, ch0ndroitin sulfate). 
the sulfation of glycosaminoglycan  chains during their bio- 
synthesis (Farley et al., 1978; Keller and Keller, 1987; Keller 
et al., 1989). To determine the effectiveness  of chlorate treat- 
ment on reducing proteoglycan sulfation in MM14 cells, we 
examined the reduction in charge density of glycosaminogly- 
cans derived from proliferating cells cultured in the presence 
or absence of 10 mM sodium chlorate. Radiosulfate incor- 
poration into all newly synthesized GAGs was reduced by 
89 %. Furthermore, DEAE-Sephacel chromatography dem- 
onstrated that whereas HSPG and CSPG elute at 0.45 and 
0.7 M NaCI, respectively, labeled glycosaminoglycans from 
chlorate-treated cells eluted at ,x,0.35 M NaC1, approaching 
that of hyaluronic acid, a  nonsulfated GAG (Fig.  3). 
Chlorate Reduces Low and High AJ~inity Binding 
of  FGFs 
We analyzed  low and high affinity  binding sites for aFGF and 
bFGF on MM14 cells as described in Materials and Meth- 
ods. For bFGF, low affinity sites were defined as those from 
which bFGF is released by a 2.0 M NaCI wash at neutral pH, 
whereas high affinity sites are those from which bFGF is 
released by a subsequent 2.0 M NaCI wash at pH 4.0.  For 
aFGF, the NaC1 wash was 0.75 M, as this factor exhibits a 
lower affinity for beparin  than bFGE  Although previous 
work has suggested that binding to low affinity sites is to 
HSPG and high affinity sites are tyrosine kinases, recently 
published data identify high affinity binding sites as a com- 
plex of HSPG and FGF receptor (Rapraeger et al.,  1991; 
Yayon et al., 1991). As expected, chlorate treatment reduces 
low affinity binding of ~25I-aFGF and ~I-bFGF (Fig. 4 a). 
Chlorate inhibition of FGF binding to low affinity sites for 
both FGFs is reversed by the simultaneous addition of so- 
dium sulfate, which restores GAG sulfation (Fig. 4 a). Ap- 
proximately 10-fold more bFGF binds to low affinity sites 
than aFGE  This may be due either to a higher affinity of 
bFGF for HSPG or bFGF recognition of a wider range of 
binding  sites on the  HSPGs.  Binding of both aFGF and 
bFGF to high affinity sites is also significantly reduced by 
chlorate treatment and restored by the simultaneous addition 
of sulfate (Fig. 4 b). Despite the differences in low affinity 
binding, aFGF and hFGF bind to a similar number of high 
affinity sites. 
Chlorate Blocks the F_~ct of bFGF on 
Myogenic Differentiation 
MM14 skeletal muscle myoblasts are dependent on FGF for 
repression of myogenesis. Withdrawal of FGF results in the 
initiation of an irreversible differentiation program, includ- 
ing expression of muscle-specific genes and fusion into mul- 
tinucleated myotubes. Treatment of MM14 cells with chlo- 
rate caused no reduction in cell viability based on counting 
cells. The number of  nuclei in chlorate treated cultures is vir- 
tually identical to the number of nuclei in untreated cultures 
grown to the same density or treated with both chlorate and 
sulfate (Fig. 5). However,  in cells treated with chlorate the 
majority of cells have fused as documented by the number 
of nuclei present in myotubes, indicating that the cells are 
terminally differentiated. Thus, chlorate treatment induces 
terminal differentiation and does not cause a reduction in the 
number of cells before or following differentiation. 
To  quantitatively  analyze  the  effects  of  chlorate  and 
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MM14 cells. MM14 myoblasts were plated as described for Fig. 4 
at 5  x  104 for control and chlorate plus sulfate treatments and 
1 x  llY cells per dish for chlorate, respectively, so that the final 
cell numbers were identical for all treatments 24 h later at which 
time they were fixed. The number of  nuclei present in myotubes and 
in single cells were scored. Nuclei present in myotubes (~), and 
nuclei in single cells ([]). 
Figure 4. Binding of aFGF and bFGF to MM14 myoblast high and 
low affinity sites is reduced by sodium chlorate treatment. MM14 
myoblasts were passaged and replated in 35-mm dishes at 1 x  106 
cells/dish, and incubated in the presence of 30 mM sodium chlo- 
rate, or no treatment for 2 h. Cells were incubated with 200 pM 
125I-bFGF  (1~) and  125I-aFGF (6)  and  low  (.4) and  high 
(B) affinity binding was determined. The respective cpms for ~25I- 
bFGF and ~zsI-aFGF were: control low affinity, 41,114 +  2,161 
and 4,775 +  699; control high affinity, 5,865 5:1,949 and 6,562 
+ 409; plus chlorate low affinity, 19,010 5:2,171 and 3,070 + 853; 
plus chlorate high affinity, 1,167 + 287 and 1,651 + 328; plus chlo- 
rate and sulfate low affinity: 48,795 5:2,818 and 4,573 5: 231; and 
plus chlorate and sulfate high affinity, 6,170 5:3,073 and 6,066 + 
707. Data represent the mean and SD from triplicate points. The 
experiment was repeated twice with similar results. 
heparitinase treatments, we monitored cell cycle exit, which 
is the first phenotypic change that occurs upon initiation of 
differentiation (Olwin and Hauschka, 1986). Treatment with 
sodium chlorate resulted in a  dose-dependent loss  in the 
bFGF response with a complete loss occurring at 30 mM so- 
dium  chlorate  (Fig.  6  a).  This  is  reversed  in  a  dose- 
dependent manner by the simultaneous addition of sodium 
sulfate; complete reversal occurs at 3 to 10 mM sodium sul- 
fate (Fig. 6 b).  The loss of FGF responsiveness is not due 
to changes in the ionic strength of the medium and is specific 
for chlorate as addition of 40 mM sodium chloride had no 
effect  on the proliferation or differentiation of MM14 skeletal 
muscle cells (data not shown).  The effects of chlorate on 
bFGF high affinity binding are consistent with the hypothesis 
that high affinity bFGF binding requires sulfated glycosami- 
noglycans. 
HSPG Is Required for aFGF  and K-FGF  Repression of 
MMI4 Myoblast Differentiation 
We have tested several additional members of the FGF fam- 
ily, aFGE K-FGE FGF-5 (Zhan et al., 1988), and KGF (ker- 
atinocyte growth factor) (Rubin et al., 1989), for prevention 
of MM14 cell cycle exit. Although FGF-5 and KGF were not 
active on these cells (data not shown), aFGF and K-FGF 
repressed differentiation and maintained cell growth  in  a 
manner analogous to bFGF (Fig. 7). Heparan sulfate is also 
required for the action of aFGF and K-FGF on MM14 myo- 
blasts  (Fig.  7).  Simultaneous  addition  of sodium  sulfate 
reversed the chlorate inhibition for all three growth factors. 
Addition of  Heparin to Chlorate-treated 
MM14 .Myoblasts Restores the Action of  aFGF, 
bFGF, and K-FGF 
Addition of  heparin in the presence of  maximally stimulating 
concentrations of aFGF, bFGF, and K-FGF restores the bio- 
logical action of all three factors in chlorate-treated cells 
(Fig. 8). In this experiment [3H]thymidine incorporation is 
normalized to the response elicited by the same concentra- 
tions of factors in untreated cells. Chlorate treatment abol- 
ishes the action of all three growth factors, but low heparin 
concentrations restore it. The ECsos for heparin stimulation 
of K-FGF, bFGF, and aFGF activities were 0.1, 0.1, and 1.0 
#g/ml, respectively. Addition of higher hcpadn concentra- 
tions results in a greater FGF response for aFGF and K-FGF 
than that seen in untreated cells. The restoration of FGF ac- 
tion by the addition of heparin demonstrates that the FGF 
signalling  pathway  for these three FGFs  is  unaffected by 
treatment of the cells with sodium chlorate. These data also 
provide additional evidence for the requirement of heparan 
Olwin and Rapraeger FGF Signalling  Depends on Heparan Sulfate  635 Figure 6. Chlorate inhibition and sulfate recovery of FGF-mediated repression of myogenesis. MM14 myoblast cultures were passaged 
and I~'plated in 24-well dishes containing 200 pM bFGF in the presence of increasing concentrations of sodium chlorate (A, ca), 30 mM 
sodium chlorate and increasing concentrations of sodium sulfate (B, B). The [3H]thymidine  incorporation in each treatment was normal- 
ized to that of untreated cells (maximum of 3,595 cpm). The background was not subtracted and averaged 200 epm or 5.6% of maximum 
values, similar to the values obtained in the presence of 30 mM chlorate. Data points represent the mean and SD of triplicate points. The 
experiment was repeated three times with similar results. 
sulfate  for  FGF  action  in  repression  of MM14  myoblast 
differentiation. 
Heparitinase Reduces bFGF  Binding and 
b  FG  F Activity 
To confirm that FGF action is dependent on the presence of 
heparan sulfate, proliferating MM14 cells were treated with 
heparitinase before and during incubation with bFGF.  This 
treatment reduced the low and high affinity binding of bFGF 
by 70% (Fig. 9 a), similar to the finding with chlorate treat- 
merit.  In addition,  pH]thymidine incorporatioJa was dimin- 
ished in the cell cycle exit assay ~ig.  9  b), demonstrating 
Figure 7. Repression of MMl4 
myoblast  differentiation  by 
aFGF  and  K-FGF  requires 
HSPG. MM14 myoblasts were 
cultured  in  50  pM  aFGF, 
bFGF,  or  K-FGF containing 
either  no  additions  ([]),  30 
mM  sodium chlorate  (11), or 
30  mM  sodium  chlorate  and 
10  mM  sodium  sulfate  (~r~). 
The cells were processed and 
harvested for DNA  synthesis 
as  described  in  Fig.  6.  The 
mean and SD are from tripli- 
cate  determinations  of  two 
independent experiments. Max- 
imum [3H]thymidine incorpo- 
ration was normalized to the 
[3H]thymidine  incorporation 
obtained for the same concen- 
trations  of  each  respective 
FGF in untreated cells. Back- 
ground  incorporation  in  the 
absence  of  FGFs  was  sub- 
tracted. 
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~ig.re 8. Hepartn restores the action of aFOF, bFGF, and E-FGF 
in cldorate-treated MM]4 myohlast cultures. MM]4 cells were cul- 
tured in 30 mM sodium chlorate and 50 pM aFGF (o), bFGF (e), 
or K-FGF (-) in the presence of increasing concentrations of hep- 
arin. Cell cycle exit assays were performed as described in Fig. 6. 
Relative [~H]thymidine  incorporation in treated cells was normal- 
ized to the [3H]thymidine incorporations observed with identical 
concentrations of  the respective FGFs in untreated cells. Incorpora- 
tion in the absence of FGF ranged between 100 and 200 cpm and 
was subtracted. The data represent the mean and SD of triplicate 
points. The experiment was repeated two times with similar results. 
that the reduction in binding to heparan sulfate is reflected 
in a failure of the cells to respond to FGE 
Discussion 
Withdrawal of FGF from Gt-phase MM14 skeletal muscle 
cells for 2-3 h initiates a terminal differentiation program 
that begins with an irreversible exit from the cell cycle. We 
determined that aFGF,  bFGF, and K-FGF are capable of 
repressing differentiation, whereas FGF-5 and KGF are not. 
Treatment  of  MMI4  myoblasts  tither  with  chlorate  or 
hcparitinase initiates a terminal differentiation program that 
is indistinguishable from that induced by FGF withdrawal. 
These observations are in agreement with a model in which 
simultaneous binding of FGF to a HSPG and a tyrosine ki- 
nase is requir~ for FGF signalling (Rapraeger et al., 1991). 
Proliferating and differentiated MMI4 cells contain chon- 
droitin sulfate proteoglycans, heparan sulfate proteoglycans, 
and free heparan sulfate chains. Several differences between 
the proteoglycan content of proliferating and differentiated 
cells are seen. These include a dramatic reduction in chon- 
droitin sulfate proteoglycans and loss of syndecan but little 
change in total HSPGs. In addition, a reduction in the free 
heparan sulfate chains is observed. These chains are likely 
to result from rapid breakdown of HSPGs,  Rapid HSPG 
turnover is also suggested by the fact that the chlorate effect 
on MM14 cells is observed within 2  to 4  h of its addition, 
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Figure  9.  Heparitinase treat- 
ment reduces  bFGF binding 
and activity. (A) MM14 ceils 
were cultured as described in 
Fig. 4 and treated with hepari- 
tinase  for 3  h  at  37~  and 
t2SI-bFGF binding was deter- 
mined as described in Fig. 4. 
(B)  MM14  cultures  were 
treated continuously  with hepa- 
ritinase and cell cy:le exit as- 
says performed as described in 
Fig. 6.  (~, no treatment; i, 
heparitinase treatment). 
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sulfated counterparts. A reduction in the synthesis of sulfated 
GAGs during differentiation of chick primary skeletal mus- 
cle cultures (Angello and Hauschka,  1979)  demonstrates 
that the changes observed in the MM14 cell line also occur 
in primary culture. 
FGF binding to a subset of low affinity sites is critical for 
FGF action; this subset is HSPG. Treatment of proliferating 
myoblasts with  30  mM  chlorate reduces binding of t25I- 
bFGF and ~25I-aFGF to low affinity sites by 56 and 36%, 
respectively. In contrast to the reduction in low affinity FGF 
binding, 10 mM chlorate reduced GAG sulfation by almost 
90 % and 30 mM chlorate should be even more effective. If 
low affinity binding of ~25I-bFGF and ~25I-aFGF was exclu- 
sively to HSPG then a reduction of at least 90% would be 
expected. This suggests that the low affinity sites are likely 
to be a combination of  HSPG and non-GAG proteins and that 
the non-GAG sites are incapable of promoting high affinity 
binding and FGF signalling. This is clearly evident for aFGF 
where 64% of the low affinity binding is to non-GAG sites. 
These data suggest that FGF signalling requires that FGFs 
must be bound to HSPG and not simply be localized at the 
cell surface. 
Restoration of FGF-mediated expression of differentiation 
in chlorate treated cells with FGF and heparin indicates a 
specific requirement of heparin or heparan sulfate glycos- 
aminoglycans for FGF action. As soluble heparin restores 
FGF activity in chlorate treated cells, GAG chain attachment 
to the core proteins is not necessary. Although the maximum 
response elicited by bFGF in untreated cells and in chlorate 
treated cells with heparin is identical, the activities of aFGF 
and K-FGF in chlorate treated cells plus heparin are substan- 
tially greater than in untreated cells. Either the addition of 
soluble heparin stabilizes these FGFs in the culture medium 
or the cell surface HSPGs are not functioning to yield the 
maximum response in untreated cells. The latter possibility 
is interesting as it implies that specific GAG sequences may 
be involved in signalling for different FGFs. 
We have demonstrated that three different forms of FGF 
require  heparan  sulfate for FGF  signalling,  suggesting a 
universal requirement for heparan sulfate. This requirement 
may be specific for different FGF receptor and cell types. 
Four and possibly five distinct tyrosine kinase FGF receptor 
genes have been identified (Lee et al.,  1989;  Pasquale and 
Singer, 1989; Pasquale, 1990; Reid et al., 1990; Avivi et al., 
1991; Partanen et al,,  1991; Stark et al.,  1991). We deter- 
mined which FGF receptor protein tyrosine kinases are ex- 
pressed  in  MMI4  myoblasts  by  reverse  transcription  of 
mRNA isolated from proliferating cells  followed by am- 
plification using the polymerase chain reaction (Kudia, A., 
A.  Lol~z, A.  Rapraeger,  and B. B. Olwin, manuscript in 
preparation). MMI4 cells express only mouse FGF receptor 
1 or the mouse homolog offlg (Lee et al., 1989; Dionne et 
al.,  1990);  if other FGF receptors are expressed by these 
cells they are below the limits of detection. Thus, the activi- 
ties of aFGF, bFGF, and K-FGF in mouse MM14 myoblasts 
are all likely to be mediated via FGFR1. It is possible that 
all FGFs interacting with FGFR1 will require heparan sul- 
fate for high affinity FGF binding and FGF action. It is not 
yet known whether the three remaining tyrosine kinase-con- 
taining FGF receptors will also exhibit a  heparan sulfate 
requirement.  It  will  also  be  interesting  to  determine  if 
specificity resides in different HSPGs at the cell surface. The 
identification of two additional FGF receptors, one of which 
is neither a tyrosine kinase nor a HSPG may further compli- 
cate the interactions described (Burrus and Olwin,  1989; 
Sakaguchi et al., 1991). The contribution of these additional 
receptors to cell surface FGF binding and FGF signal trans- 
duction is not yet known. 
Satellite cells in vivo are likely to possess FGF receptors 
as isolated satellite cells have been shown to respond to FGF 
in culture  (Gospodarowicz et al.,  1975;  Linkhart et al., 
1981; Clegg et al., 1987). The presence ofbFGF in the base- 
ment membrane surrounding skeletal muscle provides addi- 
tional evidence that repression of satellite cell differentiation 
in vivo could be mediated by FGF (DiMario et al.,  1989; 
Joseph-Silverstein et al., 1989). Thus, differentiation of sat- 
ellite cells may depend on FGF, tyrosine kinase receptors 
and the appropriate HSPGs. A similar process may operate 
during limb development as both FGF and an FGF-binding 
HSPG (syndecan) are localized to the proliferating mesen- 
chyme in chick embryos (Joseph-Silverstein et al.,  1989; 
Solursh et al.,  1990).  Future experiments will be required 
to identify the relevant HSPGs and determine whether regu- 
lation of these molecules is an important mode for regulation 
of skeletal muscle development and regeneration. 
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